CA-IKOTEK
20.11.2023 15:01:29 CET | Business Wire | Press release
Ikotek, the leading IoT original design manufacturer (ODM), announces with immediate effect the appointment of Mathi Gurusamy as its new Chief Operating Officer (COO). In his new role, Mathi will be responsible for overseeing the company's day-to-day operations, driving strategic initiatives, and contributing to Ikotek's continued growth and success.
Mathi Gurusamy brings a wealth of expertise with over 20 years of experience in the IoT sector and electronic device industry to Ikotek. Prior to joining Ikotek, Mathi held CEO and COO positions at Mobilogix and Telit for the last 15 years. Most recently, Mathi served as Telit Cinterion’s president of its IoT solutions division after the company had acquired Mobilogix in June 2022. Renowned for his adeptness in transforming start-ups into thriving enterprises, Mathi boasts a proven track record. His achievements include securing Fortune 500 companies as clients and cultivating strategic alliances with pivotal partners in the wireless industry.
With a demonstrated ability to effectively manage and drive critical business requirements, Mathi will play a pivotal role in propelling Ikotek's sustained growth and success. His robust leadership skills and strategic vision will help scale Ikotek's business objectives in the US and globally, ensuring a seamless alignment of the company’s services and delivery functions, and continue to deliver significant business impact to Ikotek’s OEM customers globally.
“We are delighted to welcome Mathi Gurusamy to Ikotek as our new COO,” commented Joe Peterson, Ikotek CEO. “His proven track record in the IoT industry and his strategic mindset make him an excellent fit for our organization. Mathi joining Ikotek is a strong endorsement and I am confident that Mathi's leadership will play a key role in advancing Ikotek's mission and ensuring our continued growth."
Mathi Gurusamy expressed his enthusiasm for joining Ikotek, stating, "I am thrilled to be part of the Ikotek team and excited about the opportunity to contribute to the company's impressive growth history. Ikotek has a strong reputation for innovation and commercial excellence across the IoT ecosystem. The ambitious growth vision and strategy is only possible with the massive investment Ikotek and its parent company Quectel has undertaken. I look forward to working with the most talented team in the industry to drive operational efficiency and deliver excellent value to our customers."
As a vital component of the Quectel family and leveraging the significant eco-system synergies of the parent company, Ikotek stands out as the only global ODM exclusively dedicated to IoT. Providing an all-encompassing suite of IoT solutions, Ikotek serves as a comprehensive one-stop-shop covering design and development, hardware construction, testing and verification, product validation, software development, manufacturing, and certification. This integrated approach ensures the delivery of top-tier products and services aimed at minimizing complexity, accelerating time to market, mitigating risks, and optimizing costs. Ikotek's commitment lies in delivering high-quality solutions that resonate with the evolving demands of the IoT landscape.
About Ikotek USA, Inc.
Headquartered in San Diego, California, Ikotek’s core focus is on the enterprise market as it looks to develop ODM solutions to take full advantage of IoT, covering technologies from cellular connectivity, including NB-IoT and 5G, to satellite connections and from well-established IT to relative newcomers such as artificial intelligence IoT (AIoT).
For more information: www.ikotek.com or LinkedIn
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231120698687/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom